Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimal rhCG(Ovidrel®) Dose for Final Oocyte Maturation Triggering in Poor Responder During IVF and ICSI Cycles

NCT01406600 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.

NCT NCT01406600
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01406600 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimal rhCG(Ovidrel®) Dose for Final Oocyte Maturation Triggering in Poor Responder During IVF and ICSI Cycles
Lead sponsor
Seoul National University Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
September 30, 2011
Completion date
December 31, 2013
Enrollment
70 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

in vitro fertilization, poor responder